NasdaqGS - Nasdaq Real Time Price USD

Revolution Medicines, Inc. (RVMD)

38.33 +0.16 (+0.42%)
At close: May 31 at 4:00 PM EDT
39.90 +1.57 (+4.10%)
Pre-Market: 8:07 AM EDT
Loading Chart for RVMD
DELL
  • Previous Close 38.17
  • Open 38.51
  • Bid 38.31 x 100
  • Ask 38.39 x 300
  • Day's Range 37.90 - 39.25
  • 52 Week Range 15.44 - 40.63
  • Volume 1,266,940
  • Avg. Volume 1,420,930
  • Market Cap (intraday) 6.324B
  • Beta (5Y Monthly) 1.46
  • PE Ratio (TTM) --
  • EPS (TTM) -3.84
  • Earnings Date Aug 6, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 45.55

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

www.revmed.com

411

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RVMD

Performance Overview: RVMD

Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RVMD
33.65%
S&P 500
10.64%

1-Year Return

RVMD
53.20%
S&P 500
25.49%

3-Year Return

RVMD
28.15%
S&P 500
25.53%

5-Year Return

RVMD
35.87%
S&P 500
56.42%

Compare To: RVMD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RVMD

Valuation Measures

Annual
As of 5/31/2024
  • Market Cap

    6.32B

  • Enterprise Value

    4.71B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.10k

  • Price/Book (mrq)

    3.67

  • Enterprise Value/Revenue

    1.03k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -22.11%

  • Return on Equity (ttm)

    -36.17%

  • Revenue (ttm)

    4.57M

  • Net Income Avi to Common (ttm)

    -484.27M

  • Diluted EPS (ttm)

    -3.84

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.7B

  • Total Debt/Equity (mrq)

    5.10%

  • Levered Free Cash Flow (ttm)

    -236.99M

Research Analysis: RVMD

Company Insights: RVMD

Research Reports: RVMD

People Also Watch